021-51111890
购物车（）
sales@molnova.cn
2-Bromohexadecanoic acid
CAS No. 18263-25-7
2-Bromohexadecanoic acid ( 2-BP | 2-bromopalmitate )
产品货号. M28032 CAS No. 18263-25-7
2-bromohexadecanoic Acid (2-BP, 2-bromopalmitate) 是一种不可代谢的棕榈酸酯类似物，可用作棕榈酰化抑制剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥300 | 有现货 |
|
| 10MG | ￥478 | 有现货 |
|
| 25MG | ￥729 | 有现货 |
|
| 50MG | ￥940 | 有现货 |
|
| 100MG | ￥1393 | 有现货 |
|
| 500MG | ￥3507 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称2-Bromohexadecanoic acid
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述2-bromohexadecanoic Acid (2-BP, 2-bromopalmitate) 是一种不可代谢的棕榈酸酯类似物，可用作棕榈酰化抑制剂。
-
产品描述2-bromohexadecanoic acid (2-BP, 2-bromopalmitate) is a non-metabolizable palmitate analogue, which can be used as palmitoylation inhibitor. 2-BP directly and irreversibly inhibits the palmitoyltransferase activity of all DHHC (Asp-His-His-Cys) proteins.(In Vitro):2-Bromohexadecanoic acid induces the interactions between GSDME-N and GSDME-C, and inhibits the GSDME-C palmitoylation, exhibiting chemotherapyinduced pyroptosis.
-
体外实验——
-
体内实验——
-
同义词2-BP | 2-bromopalmitate
-
通路Others
-
靶点Other Targets
-
受体Antioxidant|DPPH
-
研究领域——
-
适应症——
化学信息
-
CAS Number18263-25-7
-
分子量335.326
-
分子式C16H31BrO2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 100 mg/mL (298.22 mM)
-
SMILESCCCCCCCCCCCCCCC(Br)C(O)=O
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Tjahjandarie Tjitjik, Tanjung, Mulyadi. Phenolic compounds from the stem bark of Erythrina orientalis and their cytotoxic and antioxidant activities. Der Pharma Chemica, 2015 , 7 (1) :206-211.
产品手册
关联产品
-
Dolasetron
Dolasetron (MDL-73147) 是一种血清素 5-HT3 受体拮抗剂，用于治疗化疗后的恶心和呕吐。
-
Pinostrobin chalcone
Pinostrobin chalcone, a chalcone analog isolated from the leguminous plant, Mucuna pruriens, exhibits anticancer activity with an IC50 value of 20.42±2.23 μg/mL against MDA-MB-231 and 22.51±0.42 μg/mL against the HT-29 colon cancer cell line.
-
Rosarin
Rosarin 具有抗炎和神经保护作用。 Rosarin 抑制小鼠肾脏和大脑前额皮质中促炎因子 iNOS、IL-1 β 和 TNF-α 的表达。
